Aldehyde dehydrogenase inhibitors promote DNA damage in ovarian cancer and synergize with ATM/ATR inhibitors

Conclusions: ALDHi can be used to induce DNA DSB in cancer cells and synergize with inhibitors the ATM/ATR pathway. Our data suggest a novel therapeutic approach to target HR proficient ovarian cancer cells.

Source: Theranostics - April 19, 2021 Category: Molecular Biology Authors: Edward Grimley, Alexander J. Cole, Thong T. Luong, Stacy C. McGonigal, Sarah Sinno, Dongli Yang, Kara A. Bernstein, Ronald J. Buckanovich Tags: Research Paper Source Type: research